Why Patient Experience is Driving New Engagement Models
Specialty therapies continue to drive growth in the pharmaceutical industry, with spending and treatment complexity increasing across rare and specialty disease categories. While scientific innovation has expanded treatment possibilities, the patient experience required to access and remain on therapy has become increasingly complex. Patients often encounter multiple barriers—including diagnosis delays, coverage challenges, affordability concerns, and fragmented coordination across providers, payers, pharmacies, HUBs, and support vendors.
Despite significant investment in patient support infrastructure, many programs remain heavily focused on back-end access functions, leaving critical engagement needs unmet. As a result, patients may experience confusion, delays, abandonment, and early discontinuation that can affect both outcomes and therapy success.
Industry stakeholders increasingly recognize that operational infrastructure alone is insufficient. Effective support requires a dedicated front-end engagement model that combines human connection, education, guidance, and proactive outreach to help patients and healthcare providers navigate complexity and maintain momentum throughout the treatment experience.
This paper examines the factors contributing to patient journey breakdowns, the role of front-end engagement in addressing those challenges, the growing emphasis on patient experience as a strategic investment area, and the value of specialized engagement models designed to improve therapy initiation, persistence, and overall support experiences.
Offered Free by: Momentum Life Sciences
See All Resources from: Momentum Life Sciences
